Yale Law School Center for the Study of Corporate Law

20^th Anniversary · 1999 - 2019

November 8, 2018: “Law, Finance, and Innovation in Pharmaceutical R&D”

Esther S. Kim & Andrew W. Lo, The “New” Venture Philanthropy: A Case Study of the Cystic Fibrosis Foundation (Jul. 4, 2017 version)
Adam Jorring, Andrew W. Lo, Tomas J. Philipson, Manita Singh, & Richard T. Thakor, Sharing R&D Risk in Healthcare via FDA Hedges (Working Paper; January 2018 Draft)
Andrew W. Lo & Sourya V. Naraharisetti, Special Case Studies: New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, 12(1) Journal of Investment Management 4 (2014)
Vivek Ramaswamy, Video of Remarks at the First Annual Roivant Pipeline Day
Randall Smith, The Private Equity Firm that Quietly Profits on Top-Selling Drugs, New York Times, Jul. 8, 2017
Richard T. Thakor, Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, & Andrew W. Lo, Just how good an investment is the biopharmaceutical sector?, 35(12) Nature Biotechnology (2017)
Richard T. Thakor, Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, & Andrew W. Lo, Supplementary Information for: Just how good an investment is the biopharmaceutical sector? (Working Paper)
Teresa Watanabe, UCLA will get hundreds of millions for rights to prostate cancer drug, Los Angeles Times (Mar. 4, 2016)
Janet Woodcock, Expediting drug development for serious illness: Trade-offs between patient access and certainty, 15(3) Clinical Trials 230 (2018)